| Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa AJ Kunz Coyne, A El Ghali, D Holger, N Rebold, MJ Rybak Infectious diseases and therapy 11 (2), 661-682, 2022 | 125 | 2022 |
| Short-term sleep deprivation leads to decreased systemic redox metabolites and altered epigenetic status MS Trivedi, D Holger, AT Bui, TJA Craddock, JL Tartar PloS one 12 (7), e0181978, 2017 | 92 | 2017 |
| Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination R Kebriaei, KL Lev, RM Shah, KC Stamper, DJ Holger, T Morrisette, ... Microbiology Spectrum 10 (2), e00411-22, 2022 | 23 | 2022 |
| Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 22 | 2021 |
| Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections D Holger, R Kebriaei, T Morrisette, K Lev, J Alexander, M Rybak Antibiotics 10 (5), 556, 2021 | 18 | 2021 |
| Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility AJK Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, T Morrisette, ... Antibiotics 11 (9), 1175, 2022 | 15 | 2022 |
| Bacteriophage‐antibiotic combination therapy for multidrug‐resistant Pseudomonas aeruginosa: In vitro synergy testing DJ Holger, KL Lev, R Kebriaei, T Morrisette, R Shah, J Alexander, ... Journal of Applied Microbiology 133 (3), 1636-1649, 2022 | 13 | 2022 |
| COVID-19: before the fall, an evidence-based narrative review of treatment options N Rebold, D Holger, S Alosaimy, T Morrisette, M Rybak Infectious Diseases and Therapy 10, 93-113, 2021 | 12 | 2021 |
| Optimization of phage-antibiotic combinations against Staphylococcus aureus biofilms R Kebriaei, SM Lehman, RM Shah, KC Stamper, AJ Kunz Coyne, ... Microbiology Spectrum 11 (3), e04918-22, 2023 | 11 | 2023 |
| Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report DJ Holger, AJ Kunz Coyne, JJ Zhao, A Sandhu, H Salimnia, MJ Rybak Open forum infectious diseases 9 (4), ofac092, 2022 | 10 | 2022 |
| Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDR Enterococcus faecium K Lev, AJ Kunz Coyne, R Kebriaei, T Morrisette, K Stamper, DJ Holger, ... Antibiotics 11 (3), 392, 2022 | 10 | 2022 |
| Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure N Rebold, AM Lagnf, S Alosaimy, DJ Holger, P Witucki, A Mannino, ... Microbiology Spectrum 11 (1), e02647-22, 2023 | 7 | 2023 |
| Nephrotoxicity of vancomycin in combination with beta-lactam agents: ceftolozane-tazobactam vs piperacillin-tazobactam S Alosaimy, AM Lagnf, ALV Hobbs, M Mubarez, WD Kufel, T Morrisette, ... Clinical Infectious Diseases 76 (3), e1444-e1455, 2023 | 7 | 2023 |
| Evaluation of bacteriophage cocktails alone and in combination with daptomycin against daptomycin-nonsusceptible Enterococcus faecium T Morrisette, KL Lev, GS Canfield, BA Duerkop, R Kebriaei, KC Stamper, ... Antimicrobial Agents and Chemotherapy 66 (1), e01623-21, 2022 | 7 | 2022 |
| Phage cocktails with daptomycin and ampicillin eradicates biofilm-embedded multidrug-resistant Enterococcus faecium with preserved phage susceptibility. Antibiotics (Basel) 11 … AJ Kunz Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, ... | 6 | 2022 |
| High-dose cefepime vs carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC β-lactamase production AJ Kunz Coyne, A El Ghali, K Lucas, P Witucki, N Rebold, DJ Holger, ... Open Forum Infectious Diseases 10 (3), ofad034, 2023 | 4 | 2023 |
| Impact of ceftolozane–tazobactam vs. best alternative therapy on clinical outcomes in patients with multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa … DJ Holger, NS Rebold, S Alosaimy, T Morrisette, A Lagnf, AC Belza, ... Infectious Diseases and Therapy 11 (5), 1965-1980, 2022 | 4 | 2022 |
| Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes A El Ghali, T Morrisette, S Alosaimy, K Lucas, MG Tupayachi-Ortiz, ... Antimicrobial agents and chemotherapy 67 (10), e00824-23, 2023 | 3 | 2023 |
| Post‐graduate pharmacy fellowships: The current state of affairs AT Elmes, DJ Holger, K Cieslak, D Desai, AJ Kunz Coyne, V Patel, ... Journal of the American College of Clinical Pharmacy 6 (2), 145-153, 2023 | 3 | 2023 |
| Clinical Characteristics associated with bacterial bloodstream coinfection in COVID-19 N Rebold, S Alosaimy, T Morrisette, D Holger, AM Lagnf, I Ansari, ... Infectious Diseases and Therapy 11 (3), 1281-1296, 2022 | 3 | 2022 |
Michael J. Rybak, Pharm.D., M.P.H., P...Wayne State UniversityVerified email at wayne.edu
